TSX symbol: SBS
- Maurice Moloney, Ph.D. receives ASTech Award for outstanding
contribution to science and technology in Alberta -
CALGARY, Oct. 24 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that its Founder and Chief Scientific Officer, Dr. Maurice Moloney, received the ASTech Award for Innovation in Agricultural Science, sponsored by AVAC Ltd. and Dow AgroSciences Canada Ltd., at the 2007 ASTech Gala held on October 19, 2007 in Calgary, Alberta.
"Dr. Moloney's contributions to the scientific and agricultural sectors in Alberta make him a deserving recipient of this award. Maurice is truly one of the great plant molecular biologists of our generation," said Ross Bricker, President and CEO, AVAC Ltd. "The innovative plant seed oilbody technology that Maurice developed has the potential to fundamentally transform the economics and manufacturing of pharmaceutical proteins like insulin and Apo AI. His foresight to build a broad patent portfolio around their oilbody technology positions SemBioSys as a leader in the development of plant-made pharmaceuticals."
Dr. Moloney founded SemBioSys in 1994 and has been the Company's Chief Scientific Officer since July 2001. Dr. Moloney held the Natural Sciences and Engineering Research Council of Canada (NSERC) Industrial Research Chair in Plant Biotechnology from 1995 to 2003 and has been a professor in the Department of Biological Sciences at the University of Calgary since 1987. Dr. Moloney has published more than 70 original research papers and is an inventor on over 25 issued or pending patent families. He received his B.Sc. in Organic Chemistry from Imperial College at the University of London and his doctorate in Plant Biochemistry from Leicester Polytechnic in the United Kingdom.
The AVAC / Dow AgroSciences / ASTech Award is presented to an individual, team of individuals, or company having demonstrated exceptional innovation or having developed a technology of significance to Alberta's agriculture, agrifood, and agrivalue(TM) industries.
About SemBioSys Genetics Inc. (www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.
About ASTech (ww.astech.ab.ca)
The Alberta Science and Technology (ASTech) Leadership Foundation was created to celebrate the achievements of science and technology in Alberta. The foundation is a private, non-profit society supported by 19 patron organizations from the private and public sectors, all with a shared interest in showcasing the excellence in Alberta's science and technology community. ASTech is the premiere organization in Alberta that works to generate widespread public awareness for these worthy achievements in science and technology.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.